Imugene Ltd has released a press release.
Response to ASX Aware Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Acquisition of immuno-oncology technology
- Leslie Chong Appointed Chief Executive Officer
- Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
- Imugene Share Placement raises $3.2 million
- Imugene receives $1.3m R&D Tax Refund
Later from Imugene
- Imugene progresses mimotope platform
- BMC Cancer journal publishes encouraging HER-Vaxx research
- Intellectual Property Strengthened Around Lead Clinical Drug
- Half Year Report and Accounts
- $1.35 million Options Underwritten
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene